Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease (original) (raw)

• European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) & European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 64, 1388–1402 (2016).
  Google Scholar
• Lonardo, A. et al. Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups. Dig. Liver Dis. 47, 997–1006 (2015).
  Article PubMed Google Scholar
• Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73–84 (2016).
  Article PubMed Google Scholar
• Tilg, H., Moschen, A. R. & Roden, M. NAFLD and diabetes mellitus. Nat. Rev. Gastroenterol. Hepatol. 14, 32–42 (2017).
  Article PubMed CAS Google Scholar
• Targher, G., Day, C. P. & Bonora, E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N. Engl. J. Med. 363, 1341–1350 (2010).
  Article PubMed CAS Google Scholar
• Byrne, C. D. & Targher, G. NAFLD: a multisystem disease. J. Hepatol. 62, S47–64 (2015).
  Article PubMed Google Scholar
• Adams, L. A., Anstee, Q. M., Tilg, H. & Targher, G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 66, 1138–1153 (2017).
  Article PubMed Google Scholar
• Younossi, Z. M. et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 64, 1577–1586 (2016).
  Article PubMed Google Scholar
• Perseghin, G. et al. Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology 47, 51–58 (2008).
  Article PubMed CAS Google Scholar
• Rijzewijk, L. J. et al. Effects of hepatic triglyceride content on myocardial metabolism in type 2 diabetes. J. Am. Coll. Cardiol. 56, 225–233 (2010).
  Article PubMed CAS Google Scholar
• Lautamaki, R. et al. Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 291, E282–E290 (2006).
  Article PubMed CAS Google Scholar
• Goland, S. et al. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J. Clin. Gastroenterol. 40, 949–955 (2006).
  Article PubMed Google Scholar
• Fallo, F. et al. Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension. Nutr. Metab. Cardiovasc. Dis. 19, 646–653 (2009).
  Article PubMed CAS Google Scholar
• Fotbolcu, H. et al. Impairment of the left ventricular systolic and diastolic function in patients with non-alcoholic fatty liver disease. Cardiol. J. 17, 457–463 (2010).
  PubMed Google Scholar
• Mantovani, A., Zoppini, G., Targher, G., Golia, G. & Bonora, E. Non-alcoholic fatty liver disease is independently associated with left ventricular hypertrophy in hypertensive Type 2 diabetic individuals. J. Endocrinol. Invest. 35, 215–218 (2012).
  Article PubMed CAS Google Scholar
• Bonapace, S. et al. Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes. Diabetes Care 35, 389–395 (2012).
  Article PubMed PubMed Central CAS Google Scholar
• Hallsworth, K. et al. Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease. J. Hepatol. 58, 757–762 (2013).
  Article PubMed Google Scholar
• Kim, N. H. et al. Non-alcoholic fatty liver disease, metabolic syndrome and subclinical cardiovascular changes in the general population. Heart 100, 938–943 (2014).
  Article PubMed CAS Google Scholar
• Karabay, C. Y. et al. Impaired left ventricular mechanics in nonalcoholic fatty liver disease: a speckle-tracking echocardiography study. Eur. J. Gastroenterol. Hepatol. 26, 325–331 (2014).
  Article PubMed Google Scholar
• VanWagner, L. B. et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: a population-based study. Hepatology 62, 773–783 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Cassidy, S. et al. Cardiac structure and function are altered in type 2 diabetes and non-alcoholic fatty liver disease and associate with glycemic control. Cardiovasc. Diabetol. 14, 23 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Kocabay, G. et al. Left atrial deformation parameters in patients with non-alcoholic fatty liver disease: a 2D speckle tracking imaging study. Clin. Sci. 126, 297–304 (2014).
  Article PubMed Google Scholar
• Graner, M. et al. Ectopic fat depots and left ventricular function in nondiabetic men with nonalcoholic fatty liver disease. Circ. Cardiovasc. Imag. 8, e001979 (2015).
  Article Google Scholar
• Mantovani, A. et al. Nonalcoholic fatty liver disease is independently associated with early left ventricular diastolic dysfunction in patients with type 2 diabetes. PLoS ONE 10, e0135329 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Petta, S. et al. Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: association with the severity of liver disease. J. Hepatol. 62, 928–933 (2015).
  Article PubMed Google Scholar
• Sunbul, M. et al. Nonalcoholic steatohepatitis score is an independent predictor of right ventricular dysfunction in patients with nonalcoholic fatty liver disease. Cardiovasc. Ther. 33, 294–299 (2015).
  Article PubMed Google Scholar
• Psychari, S. N. et al. Epicardial fat in nonalcoholic fatty liver disease: properties and relationships with metabolic factors, cardiac structure, and cardiac function. Angiology 67, 41–48 (2016).
  Article PubMed CAS Google Scholar
• Ozveren, O. et al. Doppler tissue evaluation of atrial conduction properties in patients with non-alcoholic fatty-liver disease. Ultrason. Imag. 38, 225–235 (2016).
  Article Google Scholar
• Widya, R. L. et al. Association between hepatic triglyceride content and left ventricular diastolic function in a population-based cohort: the Netherlands epidemiology of obesity study. Radiology 279, 443–450 (2016).
  Article PubMed Google Scholar
• Trovato, F. M. et al. Echocardiography and NAFLD (non-alcoholic fatty liver disease). Int. J. Cardiol. 221, 275–279 (2016).
  Article PubMed Google Scholar
• Jung, J. Y. et al. Effect of non-alcoholic fatty liver disease on left ventricular diastolic function and geometry in the Korean general population. Hepatol. Res. 47, 522–532 (2017).
  Article PubMed Google Scholar
• Simon, T. G., Bamira, D. G., Chung, R. T., Weiner, R. B. & Corey, K. E. Nonalcoholic steatohepatitis is associated with cardiac remodeling and dysfunction. Obesity 25, 1313–1316 (2017).
  Article PubMed Google Scholar
• Lee, Y. H. et al. Association of nonalcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients. J. Hepatol. 68, 764–772 (2018).
  Article Google Scholar
• Sert, A. et al. Left ventricular function by echocardiography, tissue Doppler imaging, and carotid intima-media thickness in obese adolescents with nonalcoholic fatty liver disease. Am. J. Cardiol. 112, 436–443 (2013).
  Article PubMed Google Scholar
• Alp, H. et al. Association between nonalcoholic fatty liver disease and cardiovascular risk in obese children and adolescents. Can. J. Cardiol. 29, 1118–1125 (2013).
  Article PubMed Google Scholar
• Singh, G. K. et al. Alterations in ventricular structure and function in obese adolescents with nonalcoholic fatty liver disease. J. Pediatr. 162, 1160–1168.e1 (2013).
  Article PubMed Google Scholar
• Pacifico, L. et al. Left ventricular dysfunction in obese children and adolescents with nonalcoholic fatty liver disease. Hepatology 59, 461–470 (2014).
  Article PubMed CAS Google Scholar
• Bonci, E. et al. Association of nonalcoholic fatty liver disease with subclinical cardiovascular changes: a systematic review and meta-analysis. Biomed. Res. Int. 2015, 213737 (2015).
  Article PubMed PubMed Central Google Scholar
• Dhingra, R. et al. Serum gamma-glutamyl transferase and risk of heart failure in the community. Arterioscler. Thromb. Vasc. Biol. 30, 1855–1860 (2010).
  Article PubMed PubMed Central CAS Google Scholar
• Wannamethee, S. G., Whincup, P. H., Shaper, A. G., Lennon, L. & Sattar, N. Gamma-glutamyltransferase, hepatic enzymes, and risk of incident heart failure in older men. Arterioscler. Thromb. Vasc. Biol. 32, 830–835 (2012).
  Article PubMed CAS Google Scholar
• Wang, Y. et al. Serum gamma-glutamyltransferase and the risk of heart failure in men and women in Finland. Heart 99, 163–167 (2013).
  Article PubMed CAS Google Scholar
• Valbusa, F. et al. Nonalcoholic fatty liver disease is associated with higher 1-year all-cause rehospitalization rates in patients admitted for acute heart failure. Medicine 95, e2760 (2016).
  Article PubMed PubMed Central CAS Google Scholar
• Valbusa, F. et al. Nonalcoholic fatty liver disease and increased risk of 1-year all-cause and cardiac hospital readmissions in elderly patients admitted for acute heart failure. PLoS ONE 12, e0173398 (2017).
  Article PubMed PubMed Central CAS Google Scholar
• Sato, Y. et al. Liver stiffness assessed by Fibrosis-4 index predicts mortality in patients with heart failure. Open Heart 4, e000598 (2017).
  Article PubMed PubMed Central Google Scholar
• Otto, C. M. & Prendergast, B. Aortic-valve stenosis — from patients at risk to severe valve obstruction. N. Engl. J. Med. 371, 744–756 (2014).
  Article PubMed CAS Google Scholar
• Volzke, H. et al. Heart valve sclerosis predicts all-cause and cardiovascular mortality. Atherosclerosis 209, 606–610 (2010).
  Article PubMed CAS Google Scholar
• Rossi, A. et al. Aortic and mitral annular calcifications are predictive of all-cause and cardiovascular mortality in patients with type 2 diabetes. Diabetes Care 35, 1781–1786 (2012).
  Article PubMed PubMed Central CAS Google Scholar
• O’Neal, W. T. et al. Mitral annular calcification and incident atrial fibrillation in the Multi-Ethnic Study of Atherosclerosis. Europace 17, 358–363 (2015).
  Article PubMed Google Scholar
• Markus, M. R. et al. Hepatic steatosis is associated with aortic valve sclerosis in the general population: the Study of Health in Pomerania (SHIP). Arterioscler. Thromb. Vasc. Biol. 33, 1690–1695 (2013).
  Article PubMed CAS Google Scholar
• Bonapace, S. et al. Nonalcoholic fatty liver disease is associated with aortic valve sclerosis in patients with type 2 diabetes mellitus. PLoS ONE 9, e88371 (2014).
  Article PubMed PubMed Central CAS Google Scholar
• Mantovani, A. et al. Heart valve calcification in patients with type 2 diabetes and nonalcoholic fatty liver disease. Metabolism 64, 879–887 (2015).
  Article PubMed CAS Google Scholar
• Newton, J. L. et al. Fatigue in non-alcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance. Gut 57, 807–813 (2008).
  Article PubMed CAS Google Scholar
• Liu, Y. C. et al. Influence of non-alcoholic fatty liver disease on autonomic changes evaluated by the time domain, frequency domain, and symbolic dynamics of heart rate variability. PLoS ONE 8, e61803 (2013).
  Article PubMed PubMed Central CAS Google Scholar
• Kumar, M. S. et al. Cardiovascular autonomic dysfunction in patients of nonalcoholic fatty liver disease. Int. J. Hepatol. 2016, 5160754 (2016).
  Article PubMed PubMed Central CAS Google Scholar
• Ozveren, O. et al. Deterioration of heart rate recovery index in patients with non-alcoholic fatty liver disease (NAFLD). Med. Sci. Monit. 20, 1539–1543 (2014).
  Article PubMed PubMed Central CAS Google Scholar
• Cho, K. I., Jo, E. A., Cho, S. H. & Kim, B. H. The influence of epicardial fat and nonalcoholic fatty liver disease on heart rate recovery in metabolic syndrome. Metab. Syndr. Relat. Disord. 15, 226–232 (2017).
  Article PubMed CAS Google Scholar
• Targher, G. et al. Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes. Clin. Sci. 125, 301–309 (2013).
  Article PubMed CAS Google Scholar
• Targher, G. et al. Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PLoS ONE 8, e57183 (2013).
  Article PubMed PubMed Central CAS Google Scholar
• Sinner, M. F. et al. Relation of circulating liver transaminase concentrations to risk of new-onset atrial fibrillation. Am. J. Cardiol. 111, 219–224 (2013).
  Article PubMed CAS Google Scholar
• Iscen, S. RBBB is associated with an increased risk of NAFLD in young healthy individuals. Int. J. Cardiol. 168, 4056–4057 (2013).
  Article PubMed Google Scholar
• Alonso, A. et al. Circulating levels of liver enzymes and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities cohort. Heart 100, 1511–1516 (2014).
  Article PubMed PubMed Central CAS Google Scholar
• Targher, G. et al. Association of nonalcoholic fatty liver disease with QTc interval in patients with type 2 diabetes. Nutr. Metab. Cardiovasc. Dis. 24, 663–669 (2014).
  Article PubMed Google Scholar
• Karajamaki, A. J. et al. Non-alcoholic fatty liver disease as a predictor of atrial fibrillation in middle-aged population (OPERA Study). PLoS ONE 10, e0142937 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Hung, C. S. et al. Nonalcoholic fatty liver disease is associated with QT prolongation in the general population. J. Am. Heart Assoc. 4, e001820 (2015).
  PubMed PubMed Central Google Scholar
• Markus, M. R. et al. Association between hepatic steatosis and serum liver enzyme levels with atrial fibrillation in the general population: the Study of Health in Pomerania (SHIP). Atherosclerosis 245, 123–131 (2016).
  Article PubMed CAS Google Scholar
• Mantovani, A. et al. Nonalcoholic fatty liver disease is associated with ventricular arrhythmias in patients with type 2 diabetes referred for clinically indicated 24-hour holter monitoring. Diabetes Care 39, 1416–1423 (2016).
  Article PubMed CAS Google Scholar
• Mangi, M. A. et al. Association of non-alcoholic fatty liver disease with conduction defects on electrocardiogram. Cureus 9, e1107 (2017).
  PubMed PubMed Central Google Scholar
• Karajamaki, A. J. et al. Presence of atrial fibrillation is associated with liver stiffness in an elderly Finnish population. PLoS ONE 12, e0173855 (2017).
  Article PubMed PubMed Central CAS Google Scholar
• Long, M. T. et al. Relations of liver fat with prevalent and incident atrial fibrillation in the Framingham Heart Study. J. Am. Heart Assoc. 6, e005227 (2017).
  PubMed PubMed Central Google Scholar
• Mantovani, A. et al. Nonalcoholic fatty liver disease is associated with an increased risk of heart block in hospitalized patients with type 2 diabetes mellitus. PLoS ONE 12, e0185459 (2017).
  Article PubMed PubMed Central CAS Google Scholar
• Lip, G. Y., Tse, H. F. & Lane, D. A. Atrial fibrillation. Lancet 379, 648–661 (2012).
  Article PubMed Google Scholar
• Wijarnpreecha, K., Boonpheng, B., Thongprayoon, C., Jaruvongvanich, V. & Ungprasert, P. The association between non-alcoholic fatty liver disease and atrial fibrillation: a meta-analysis. Clin. Res. Hepatol. Gastroenterol. 41, 525–532 (2017).
  Article PubMed Google Scholar
• Straus, S. M. et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J. Am. Coll. Cardiol. 47, 362–367 (2006).
  Article PubMed Google Scholar
• Coumbe, A. G. et al. Long-term follow-up of older patients with Mobitz type I second degree atrioventricular block. Heart 99, 334–338 (2013).
  Article PubMed Google Scholar
• Kwok, C. S. et al. Prolonged PR interval, first-degree heart block and adverse cardiovascular outcomes: a systematic review and meta-analysis. Heart 102, 672–680 (2016).
  Article PubMed CAS Google Scholar
• Gregor, M. F. & Hotamisligil, G. S. Inflammatory mechanisms in obesity. Annu. Rev. Immunol. 29, 415–445 (2011).
  Article PubMed CAS Google Scholar
• Tilg, H. & Moschen, A. R. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52, 1836–1846 (2010).
  Article PubMed CAS Google Scholar
• Liu, Y. L. et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat. Commun. 5, 4309 (2014).
  Article PubMed PubMed Central CAS Google Scholar
• Anstee, Q. M. & Day, C. P. The genetics of nonalcoholic fatty liver disease: spotlight on PNPLA3 and TM6SF2. Semin. Liver Dis. 35, 270–290 (2015).
  Article PubMed CAS Google Scholar
• Kahali, B. et al. TM6SF2: catch-22 in the fight against nonalcoholic fatty liver disease and cardiovascular disease? Gastroenterology 148, 679–684 (2015).
  Article PubMed Google Scholar
• Anstee, Q. M., Seth, D. & Day, C. P. Genetic factors that affect risk of alcoholic and nonalcoholic fatty liver disease. Gastroenterology 150, 1728–1744.e7 (2016).
  Article PubMed Google Scholar
• Tilg, H., Moschen, A. R. & Szabo, G. Interleukin-1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology 64, 955–965 (2016).
  Article PubMed CAS Google Scholar
• Cai, D. et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat. Med. 11, 183–190 (2005).
  Article PubMed PubMed Central CAS Google Scholar
• Arkan, M. C. et al. IKK-beta links inflammation to obesity-induced insulin resistance. Nat. Med. 11, 191–198 (2005).
  Article PubMed CAS Google Scholar
• Kiechl, S. et al. Blockade of receptor activator of nuclear factor-kappaB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat. Med. 19, 358–363 (2013).
  Article PubMed CAS Google Scholar
• Mohamed-Ali, V. et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J. Clin. Endocrinol. Metab. 82, 4196–4200 (1997).
  PubMed CAS Google Scholar
• Moschen, A. R. et al. Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor alpha expression. Gut 59, 1259–1264 (2010).
  Article PubMed CAS Google Scholar
• Byrne, C. D. & Targher, G. Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 34, 1155–1161 (2014).
  Article PubMed CAS Google Scholar
• Katsiki, N., Athyros, V. G. & Mikhailidis, D. P. Abnormal peri-organ or intra-organ fat (APIFat) deposition: an underestimated predictor of vascular risk? Curr. Vasc. Pharmacol. 14, 432–441 (2016).
  Article PubMed CAS Google Scholar
• Kau, A. L., Ahern, P. P., Griffin, N. W., Goodman, A. L. & Gordon, J. I. Human nutrition, the gut microbiome and the immune system. Nature 474, 327–336 (2011).
  Article PubMed PubMed Central CAS Google Scholar
• Tilg, H. & Moschen, A. R. Food, immunity, and the microbiome. Gastroenterology 148, 1107–1119 (2015).
  Article PubMed Google Scholar
• Calder, P. C. Fatty acids and inflammation: the cutting edge between food and pharma. Eur. J. Pharmacol. 668 (Suppl. 1), S50–S58 (2011).
  Article PubMed CAS Google Scholar
• Pendyala, S., Walker, J. M. & Holt, P. R. A high-fat diet is associated with endotoxemia that originates from the gut. Gastroenterology 142, 1100–1101.e2 (2012).
  Article PubMed PubMed Central CAS Google Scholar
• Wang, Z. et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472, 57–63 (2011).
  Article PubMed PubMed Central CAS Google Scholar
• Chen, Y. M. et al. Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults. Sci. Rep. 6, 19076 (2016).
  Article PubMed PubMed Central CAS Google Scholar
• Loomba, R. et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab. 25, 1054–1062.e5 (2017).
  Article PubMed PubMed Central CAS Google Scholar
• Moschen, A. R., Kaser, S. & Tilg, H. Non-alcoholic steatohepatitis: a microbiota-driven disease. Trends Endocrinol. Metab. 24, 537–545 (2013).
  Article PubMed CAS Google Scholar
• Shanahan, F., van Sinderen, D., O’Toole, P. W. & Stanton, C. Feeding the microbiota: transducer of nutrient signals for the host. Gut 66, 1709–1717 (2017).
  Article PubMed Google Scholar
• Dusi, V., Ghidoni, A., Ravera, A., De Ferrari, G. M. & Calvillo, L. Chemokines and heart disease: a network connecting cardiovascular biology to immune and autonomic nervous systems. Mediators Inflamm. 2016, 5902947 (2016).
  Article PubMed PubMed Central CAS Google Scholar
• Lazzerini, P. E., Capecchi, P. L. & Laghi-Pasini, F. Systemic inflammation and arrhythmic risk: lessons from rheumatoid arthritis. Eur. Heart J. 38, 1717–1727 (2017).
  PubMed Google Scholar
• Yalta, T. & Yalta, K. Systemic inflammation and arrhythmogenesis: a review of mechanistic and clinical perspectives. Angiology 69, 288–296 (2017).
  Article PubMed Google Scholar
• Duewell, P. et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464, 1357–1361 (2010).
  Article PubMed PubMed Central CAS Google Scholar
• Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119–1131 (2017).
  Article PubMed CAS Google Scholar
• Monnerat, G. et al. Macrophage-dependent IL-1beta production induces cardiac arrhythmias in diabetic mice. Nat. Commun. 7, 13344 (2016).
  Article PubMed PubMed Central CAS Google Scholar
• Aschar-Sobbi, R. et al. Increased atrial arrhythmia susceptibility induced by intense endurance exercise in mice requires TNFalpha. Nat. Commun. 6, 6018 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Abramochkin, D. V. et al. TNF-alpha provokes electrical abnormalities in rat atrial myocardium via a NO-dependent mechanism. Pflugers Arch. 465, 1741–1752 (2013).
  Article PubMed CAS Google Scholar
• London, B. et al. Calcium-dependent arrhythmias in transgenic mice with heart failure. Am. J. Physiol. Heart Circ. Physiol. 284, H431–H441 (2003).
  Article PubMed CAS Google Scholar
• Kawada, H. et al. Tumor necrosis factor-alpha downregulates the voltage gated outward K+ current in cultured neonatal rat cardiomyocytes: a possible cause of electrical remodeling in diseased hearts. Circ. J. 70, 605–609 (2006).
  Article PubMed CAS Google Scholar
• Panama, B. K. et al. Nuclear factor kappaB downregulates the transient outward potassium current I(to,f) through control of KChIP2 expression. Circ. Res. 108, 537–543 (2011).
  Article PubMed CAS Google Scholar
• Fu, X. X. et al. Interleukin-17A contributes to the development of post-operative atrial fibrillation by regulating inflammation and fibrosis in rats with sterile pericarditis. Int. J. Mol. Med. 36, 83–92 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Takahashi, K. et al. High-fat diet increases vulnerability to atrial arrhythmia by conduction disturbance via miR-27b. J. Mol. Cell Cardiol. 90, 38–46 (2016).
  Article PubMed CAS Google Scholar
• Luo, B. et al. NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model. PLoS ONE 9, e104771 (2014).
  Article PubMed PubMed Central CAS Google Scholar
• Toldo, S. et al. Interleukin-1beta blockade improves left ventricular systolic/diastolic function and restores contractility reserve in severe ischemic cardiomyopathy in the mouse. J. Cardiovasc. Pharmacol. 64, 1–6 (2014).
  Article PubMed CAS Google Scholar
• Van Tassell, B. W., Raleigh, J. M. & Abbate, A. Targeting interleukin-1 in heart failure and inflammatory heart disease. Curr. Heart Fail. Rep. 12, 33–41 (2015).
  Article PubMed CAS Google Scholar
• Amdur, R. L. et al. Interleukin-6 is a risk factor for atrial fibrillation in chronic kidney disease: findings from the CRIC study. PLoS ONE 11, e0148189 (2016).
  Article PubMed PubMed Central CAS Google Scholar
• Wu, N. et al. Association of inflammatory factors with occurrence and recurrence of atrial fibrillation: a meta-analysis. Int. J. Cardiol. 169, 62–72 (2013).
  Article PubMed Google Scholar
• Chalasani, N. et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67, 328–357 (2017).
  Article PubMed Google Scholar
• Zhang, H. J. et al. Effects of moderate and vigorous exercise on nonalcoholic fatty liver disease: a randomized clinical trial. JAMA Intern. Med. 176, 1074–1082 (2016).
  Article PubMed Google Scholar
• Promrat, K. et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 51, 121–129 (2010).
  Article PubMed PubMed Central CAS Google Scholar
• Vilar-Gomez, E. et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 149, 367–378 (2015).
  Article PubMed Google Scholar
• Fontana, L., Meyer, T. E., Klein, S. & Holloszy, J. O. Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. Proc. Natl Acad. Sci. USA 101, 6659–6663 (2004).
  Article PubMed PubMed Central CAS Google Scholar
• Gupta, P. P., Fonarow, G. C. & Horwich, T. B. Obesity and the obesity paradox in heart failure. Can. J. Cardiol. 31, 195–202 (2015).
  Article PubMed Google Scholar
• Mantovani, A., Ballestri, S., Lonardo, A. & Targher, G. Cardiovascular disease and myocardial abnormalities in nonalcoholic fatty liver disease. Dig. Dis. Sci. 61, 1246–1267 (2016).
  Article PubMed Google Scholar
• Karimian, S., Stein, J., Bauer, B. & Teupe, C. Improvement of impaired diastolic left ventricular function after diet-induced weight reduction in severe obesity. Diabetes Metab. Syndr. Obes. 10, 19–25 (2017).
  Article PubMed PubMed Central Google Scholar
• Mahajan, R., Lau, D. H. & Sanders, P. Impact of obesity on cardiac metabolism, fibrosis, and function. Trends Cardiovasc. Med. 25, 119–126 (2015).
  Article PubMed CAS Google Scholar
• Heneghan, H. M., Meron-Eldar, S., Brethauer, S. A., Schauer, P. R. & Young, J. B. Effect of bariatric surgery on cardiovascular risk profile. Am. J. Cardiol. 108, 1499–1507 (2011).
  Article PubMed Google Scholar
• Poirier, P. et al. Bariatric surgery and cardiovascular risk factors: a scientific statement from the American Heart Association. Circulation 123, 1683–1701 (2011).
  Article PubMed Google Scholar
• de las Fuentes, L. et al. Effect of moderate diet-induced weight loss and weight regain on cardiovascular structure and function. J. Am. Coll. Cardiol. 54, 2376–2381 (2009).
  Article CAS Google Scholar
• Lin, J. S. et al. Behavioral counseling to promote a healthy lifestyle in persons with cardiovascular risk factors: a systematic review for the U.S. Preventive Services Task Force. Ann. Intern. Med. 161, 568–578 (2014).
  Article PubMed Google Scholar
• Hallsworth, K. et al. Modified high-intensity interval training reduces liver fat and improves cardiac function in non-alcoholic fatty liver disease: a randomized controlled trial. Clin. Sci. 129, 1097–1105 (2015).
  Article PubMed CAS Google Scholar
• Horwich, T. B. et al. The relationship between obesity and mortality in patients with heart failure. J. Am. Coll. Cardiol. 38, 789–795 (2001).
  Article PubMed CAS Google Scholar
• Bozkurt, B. & Deswal, A. Obesity as a prognostic factor in chronic symptomatic heart failure. Am. Heart J. 150, 1233–1239 (2005).
  Article PubMed Google Scholar
• Oreopoulos, A. et al. Body mass index and mortality in heart failure: a meta-analysis. Am. Heart J. 156, 13–22 (2008).
  Article PubMed Google Scholar
• Frith, J. et al. Potential strategies to improve uptake of exercise interventions in non-alcoholic fatty liver disease. J. Hepatol. 52, 112–116 (2010).
  Article PubMed Google Scholar
• Centis, E. et al. Stage of change and motivation to healthier lifestyle in non-alcoholic fatty liver disease. J. Hepatol. 58, 771–777 (2013).
  Article PubMed Google Scholar
• Angulo, P. et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149, 389–397.e10 (2015).
  Article PubMed PubMed Central Google Scholar
• Taylor, F. et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst. Rev. 1, CD004816 (2013).
  Google Scholar
• Keene, D., Price, C., Shun-Shin, M. J. & Francis, D. P. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. BMJ 349, g4379 (2014).
  Article PubMed PubMed Central CAS Google Scholar
• Gudzune, K. A. et al. Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review. Ann. Intern. Med. 160, 468–476 (2014).
  Article PubMed Google Scholar
• Dongiovanni, P. et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J. Hepatol. 63, 705–712 (2015).
  Article PubMed CAS Google Scholar
• Lonardo, A. & Loria, P. Potential for statins in the chemoprevention and management of hepatocellular carcinoma. J. Gastroenterol. Hepatol. 27, 1654–1664 (2012).
  Article PubMed CAS Google Scholar
• Rzouq, F. S. et al. Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians. Am. J. Med. Sci. 340, 89–93 (2010).
  Article PubMed Google Scholar
• Bays, H., Cohen, D. E., Chalasani, N., Harrison, S. A. & The National Lipid Association’s Statin Safety Task Force. An assessment by the statin liver safety task force: 2014 update. J. Clin. Lipidol. 8, S47–S57 (2014).
  Article PubMed Google Scholar
• Lewis, J. H. Clinical perspective: statins and the liver — harmful or helpful? Dig. Dis. Sci. 57, 1754–1763 (2012).
  Article PubMed Google Scholar
• Athyros, V. G. et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 376, 1916–1922 (2010).
  Article PubMed CAS Google Scholar
• Tikkanen, M. J. et al. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int. J. Cardiol. 168, 3846–3852 (2013).
  Article PubMed Google Scholar
• Musso, G., Gambino, R., Cassader, M. & Pagano, G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 52, 79–104 (2010).
  Article PubMed CAS Google Scholar
• Hirose, A. et al. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology 45, 1375–1381 (2007).
  Article PubMed CAS Google Scholar
• Yokohama, S. et al. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 40, 1222–1225 (2004).
  Article PubMed CAS Google Scholar
• Georgescu, E. F., Ionescu, R., Niculescu, M., Mogoanta, L. & Vancica, L. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J. Gastroenterol. 15, 942–954 (2009).
  Article PubMed PubMed Central CAS Google Scholar
• McPherson, S. et al. A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis. PLoS ONE 12, e0175717 (2017).
  Article PubMed PubMed Central CAS Google Scholar
• Sanyal, A. J. et al. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology 147, 377–384.e1 (2014).
  Article PubMed CAS Google Scholar
• Argo, C. K. et al. Effects of n-3 fish oil on metabolic and histological parameters in NASH: a double-blind, randomized, placebo-controlled trial. J. Hepatol. 62, 190–197 (2015).
  Article PubMed CAS Google Scholar
• Foretz, M., Guigas, B., Bertrand, L., Pollak, M. & Viollet, B. Metformin: from mechanisms of action to therapies. Cell Metab. 20, 953–966 (2014).
  Article PubMed CAS Google Scholar
• Chen, H. P. et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut 62, 606–615 (2013).
  Article PubMed CAS Google Scholar
• Zhang, Z. J. et al. Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 97, 2347–2353 (2012).
  Article PubMed CAS Google Scholar
• Sanyal, A. J. et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 362, 1675–1685 (2010).
  Article PubMed PubMed Central CAS Google Scholar
• Cusi, K. et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann. Intern. Med. 165, 305–315 (2016).
  Article PubMed Google Scholar
• Armstrong, M. J. et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387, 679–690 (2016).
  Article PubMed CAS Google Scholar
• Marso, S. P. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375, 311–322 (2016).
  Article PubMed PubMed Central CAS Google Scholar
• Perazzo, H. & Dufour, J. F. The therapeutic landscape of non-alcoholic steatohepatitis. Liver Int. 37, 634–647 (2017).
  Article PubMed CAS Google Scholar
• Neuschwander-Tetri, B. A. et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385, 956–965 (2015).
  Article PubMed CAS Google Scholar
• Ratziu, V. et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology 150, 1147–1159.e5 (2016).
  Article PubMed CAS Google Scholar
• Friedman, S. L. et al. A randomized, placebo-ontrolled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology https://doi.org/10.1002/hep.29477 (2018).
• Loomba, R. et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial. Hepatology 67, 549–559 (2018).
  Article CAS Google Scholar